

COVID 19 Spike Protein (South Africa Variant) Neutralization Coronavirus Monoclonal Antibody | anti-COVID-19 antibody

Anti-Spike Protein (SARS-CoV-2/South Africa Variant) Neutralization Antibody

CATALOG #

AAA62228

APPLICATIONS

Flow Cytometry, Functional Assay, Immunofluorescence, Neutralization Assay, ELISA


PRODUCT SYNONYMS

COVID 19 Spike Protein (South Africa Variant) Neutralization Coronavirus; Monoclonal Antibody; Anti-Spike Protein (SARS-CoV-2/South Africa Variant) Neutralization Antibody; 2019 Novel Coronavirus; Coronavirus; CoV; COVID-19 virus; HCoV-2; Human Coronavirus 2019; SARS2; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Spike Protein; South Africa Variant; Neutralization; anti-COVID-19 antibody

PRODUCT SPECIFICATIONS


Clonality	Monoclonal
Isotype	Human IgG
Specificity	Reacts with RBD domain of spike protein of SARS-CoV-2, including South Africa variant (B.1.351) and UK variant (B.1.1.7).
Purity/Purification	Affinity chromatography
Form/Format	1 ug/ul in PBS with 40% glycerol
Concentration	1 ug/ul (varies by lot)
Applicable Applications for anti-COVID-19 antibody	FCM/FACS (Flow Cytometry), IF (Immunofluorescence), NTRL (Neutralization Assay), ELISA
Immunogen	Recombinant spike protein of SARS-CoV-2 South Africa variant
Preparation and Storage	Store at -20 degree C; Stable for 6-months from the date of shipment when kept at 4 degree C. Non-hazardous. No MSDS required.

IMAGES



ELISA

Figure 2. Pseudoviral particle (PP) infection assay challenged by neutralizing antibody (AAA62228). HEK293-ACE2 cells infected with SARS-CoV-2 pseudoviral particles under various amounts of neutralizing antibodies, with IC50 of 42.8 ng/ml and 45 ng/ml



ELISA

Figure 1. Titration curves of anti-spike neutralization antibody (AAA62228). 96-well corning ELISA plate was coated with SARS-CoV-2 spike RBD protein at a concentration of 2 ug/ml, and with a EC50 of 12.19 ng/ml.

ADDITIONAL INFORMATION

Related Product Information for anti-COVID-19 antibody	Human monoclonal anti-spike neutralization (SARS-CoV-2/South Africa Variant) antibody Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes COVID-19 (coronavirus disease 2019), the respiratory illness responsible for the COVID-19 pandemic. There are many thousands of variants of SARS-CoV-2 have been identified throughout the world since it was first identified Wuhan China from late 2019. The genome of SARS-CoV-2 has 89% nucleotide identity with bat SARS-like-CoVZXC21 and 82% with that of human SARS-CoV. The phylogenetic trees of their orf1a/b, Spike, Envelope, Membrane and Nucleoprotein also clustered closely with those of the bat, civet and human SARS coronaviruses. However, the external subdomain of Spike's receptor binding domain (RBD) of SARS-CoV-2 shares only 40% amino acid identity with other SARS-related coronaviruses.
--	--

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://stage.aaabiotech.com/monoclonal/covid-19-spike-protein-south-africa-variant-neutralization-coronavirus-antibody-flow-cytometry-immunofluorescence-neutralization-assay-elisa/62228>